Who are Cystadane's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Vitamin B12 Coenzyme, Vitamin Q, Decitabine and cedazuridine, EnBrace HR, ASTX727, Gilteritinib + Azacitidine + Venetoclax.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/betaine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Cystadane — Competitive Intelligence Brief

Cystadane (BETAINE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Methylating Agent [EPC]. Area: Infectious Disease.

marketed Methylating Agent [EPC] Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Cystadane (BETAINE) — Recordati.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Cystadane TARGET	BETAINE	Recordati	marketed	Methylating Agent [EPC]		1996-01-01
Vitamin B12 Coenzyme	COBAMAMIDE		marketed	Methylating Agent [EPC]
Vitamin Q	UBIDECARENONE		marketed	Methylating Agent [EPC]
Decitabine and cedazuridine	Decitabine and cedazuridine	Race Oncology Ltd	marketed	Hypomethylating agent	DNA methyltransferase (DNMT)
EnBrace HR	COCARBOXYLASE	Jaymac Pharmaceuticals, LLC	marketed	Methylating Agent [EPC]
ASTX727	ASTX727	Taiho Oncology, Inc.	phase 3	Hypomethylating agent	DNA methyltransferase (DNMT)
Gilteritinib + Azacitidine + Venetoclax	Gilteritinib + Azacitidine + Venetoclax	Institute of Hematology & Blood Diseases Hospital, China	phase 3	FLT3 inhibitor + hypomethylating agent + BCL-2 inhibitor combination	FLT3, DNA methyltransferase, BCL-2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Methylating Agent [EPC] class)

· 2 drugs in this class
Jaymac Pharmaceuticals, LLC · 1 drug in this class
Recordati · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Cystadane — Competitive Intelligence Brief. https://druglandscape.com/ci/betaine. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab